Jiangsu Weikai focuses on innovative drug research and development, generic drug technology transfer, and the production and sale of pharmaceutical intermediates. The company maintains integrated R&D, production and sales systems and operates synthesis, formulation and drug analysis laboratories. It has established industrialization partnerships with multiple manufacturers to support scaling. Recently the company completed a Series C financing of over ¥450 million. Proceeds will be used to accelerate its innovative drug R&D pipeline and to expand its full-industry-chain CRO/CDMO capabilities. New investor participation and continued backing from existing shareholders signal strong market confidence in the company.

Total raised

$63M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2024